文献速递肿瘤 PET/CT核素与放射性配体治疗

成纤维细胞活化蛋白抑制剂(FAPI)PET 用于头颈癌诊断与先进靶向放疗

Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-05-23

该研究在 14 例头颈癌患者放疗前行 68Ga-FAPI PET-CT,并对比增强 CT 与 MRI 勾画肿瘤体积;结果显示肿瘤病灶 FAPI 摄取高而头颈部正常组织本底低,不同阈值下 FAPI-GTV 与 CT-GTV 存在显著差异,部分 FAPI-GTV 未被基于增强 CT 的计划靶区覆盖,作者认为需更大样本并结合组织病理学验证。

要点

  • 14 例头颈癌患者放疗前完成 68Ga-FAPI PET-CT,原发肿瘤 SUVmax 14.62 ± 4.44、SUVmean 7.41 ± 2.39。
  • 健康唾液腺本底摄取低,SUVmax 1.76 ± 0.31、SUVmean 1.23 ± 0.28。
  • FAPI 不同阈值勾画的 GTV 与 CT-GTV 27.3 ml 相比差异显著,部分 FAPI-GTV 未被 CT-PTV 覆盖。

核心结论

  • 作者首次报告 FAPI 配体在头颈癌中具有诊断与治疗潜力,但需更大样本并结合组织病理学验证。

研究设计与样本

  • 14 例头颈癌患者在放疗前除增强 CT(CE-CT)和 MRI 外,无并发症地接受了 68Ga-FAPI PET-CT 检查。
  • 先定义感兴趣体积量化肿瘤与健康实质的 SUVmean 和 SUVmax,再以肿瘤较正常组织 FAPI 增强三倍、五倍、七倍和十倍四个阈值自动生成四个大体肿瘤体积(FAPI-GTV),并与 CE-CT 和 MRI 常规勾画的 GTV(CT-GTV)比较。

主要发现

  • 生物分布分析显示肿瘤病灶 FAPI 亲和力高,例如原发肿瘤 SUVmax 14.62 ± 4.44、SUVmean 7.41 ± 2.39。
  • 头颈部健康组织本底摄取低,例如唾液腺 SUVmax 1.76 ± 0.31、SUVmean 1.23 ± 0.28。
  • CT-GTV 为 27.3 ml,FAPI 勾画的 GTV 分别为 67.7 ml(FAPI × 3,p = 0.0134)、22.1 ml(FAPI × 5,p = 0.0419)、7.6 ml(FAPI × 7,p = 0.0001)和 2.3 ml(FAPI × 10,p = 0.0001)。
  • 将 FAPI-GTV 与 CT-GTV 合并后,中位体积较 CT-GTV 显著增大:FAPI × 3 为 54.7 ml(相对增加 + 200.5%,p = 0.0005),FAPI × 5 为 15.0 ml(+ 54.9%,p = 0.0122)。
  • 多例中 FAPI-GTV 未被基于 CE-CT 的计划靶体积(CT-PTV)覆盖。

局限性

  • 作者指出需更大样本并结合组织病理学相关性的研究来验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) have been associated with the aggressive nature of head and neck cancers (HNCs). These tumours grow diffusely, leading to extremely challenging differentiation between tumour and healthy tissue. This analysis aims to introduce a novel approach of tumour detection, contouring and targeted radiotherapy of HNCs using visualisation of CAFs: PET-CT with 68Ga-radiolabeled inhibitors of FAP (FAPI). METHODS: FAPI PET-CT was performed without complications prior to radiotherapy in addition to contrast enhanced CT (CE-CT) and MRI on 14 patients with HNC. First, for tissue biodistribution analysis, volumes of interest were defined to quantify SUVmean and SUVmax in tumour and healthy parenchyma. Secondly, using four thresholds of three-, five-, seven- and tenfold increase of FAPI enhancement in the tumour as compared with normal tissue, four different gross tumour volumes (FAPI-GTV) were created automatically. These were compared with GTVs created conventionally with CE-CT and MRI (CT-GTV). RESULTS: The biodistribution analysis revealed high FAPI avidity within tumorous lesions (e.g. primary tumours, SUVmax 14.62 ± 4.44; SUVmean 7.41 ± 2.39). In contrast, low background uptake was measured in healthy tissues of the head and neck region (e.g. salivary glands: SUVmax 1.76 ± 0.31; SUVmean 1.23 ± 0.28). Considering radiation planning, CT-GTV was of 27.3 ml, whereas contouring with FAPI resulted in significantly different GTVs of 67.7 ml (FAPI × 3, p = 0.0134), 22.1 ml (FAPI × 5, p = 0.0419), 7.6 ml (FAPI × 7, p = 0.0001) and 2.3 ml (FAPI × 10, p = 0.0001). Taking these significant disparities between the GTVs into consideration, we merged FAPI-GTVs with CT-GTVs. This resulted in median volumes, that were, as compared to CT-GTVs, significantly larger with FAPI × 3 (54.7 ml, + 200.5% relative increase, p = 0.0005) and FAPI × 5 (15.0 ml, + 54.9%, p = 0.0122). Furthermore, FAPI-GTVs were not covered by CE-CT-based planning target volumes (CT-PTVs) in several cases. CONCLUSION: We present first evidence of diagnostic and therapeutic potential of FAPI ligands in head and neck cancer. Larger studies with histopathological correlation are required to validate our findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Syed M, Flechsig P, Liermann J, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020. PMID: 32447444. doi:10.1007/s00259-020-04859-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。